IQVIA (IQV) Stock Forecast & Price Target

Q: What analysts cover IQVIA?

IQVIA has been rated by research analysts at Barclays , BMO Capital Markets , Deutsche Bank Aktiengesellschaft , HSBC , JPMorgan Chase & Co. , Mizuho , Morgan Stanley , Robert W. Baird , Royal Bank Of Canada , Stifel Nicolaus , TD Cowen , Weiss Ratings , and William Blair in the past 90 days.

$262.09 +4.79 (+1.86%)

Closing price 09/11/2026 03:58 PM Eastern

Extended Trading

$263.80 +1.71 (+0.65%)

As of 09/11/2026 07:30 PM Eastern

Compare

IQVIA - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Moderate Buy

Based on 17 Analyst Ratings

Sell
0

Hold
3

Buy
14

Based on 17 Wall Street analysts who have issued ratings for IQVIA in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 17 analysts, 3 have given a hold rating, 13 have given a buy rating, and 1 has given a strong buy rating for IQV.

Consensus Price Target

$243.63
-7.05% Downside

According to the 17 analysts' twelve-month price targets for IQVIA, the average price target is $243.63. The highest price target for IQV is $288.00, while the lowest price target for IQV is $185.00. The average price target represents a forecasted downside of -7.05% from the current price of $262.09.

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Get the Latest News and Ratings for IQV and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for IQVIA and its competitors.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

IQV Analyst Ratings Over Time

Type	Current Forecast 9/13/25 to 9/13/26	1 Month Ago 8/14/25 to 8/14/26	3 Months Ago 6/15/25 to 6/15/26	1 Year Ago 9/13/24 to 9/13/25
Strong Buy	1 Strong Buy rating(s)	1 Strong Buy rating(s)	2 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	13 Buy rating(s)	13 Buy rating(s)	13 Buy rating(s)	17 Buy rating(s)
Hold	3 Hold rating(s)	3 Hold rating(s)	2 Hold rating(s)	5 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$243.63	$241.88	$224.13	$227.43
Forecasted Upside	-7.05% Downside	2.42% Upside	25.87% Upside	21.40% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Buy	Moderate Buy

IQV Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

IQV Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

IQVIA Stock vs. The Competition

Type	IQVIA	Healthcare Companies	Broader Market
Consensus Rating Score	2.88	2.30	2.53
Consensus Rating	Moderate Buy	Hold	Moderate Buy
Predicted Upside	-7.05% Downside	891.32% Upside	16.41% Upside
News Sentiment Rating	Positive News See Recent IQV News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export

Date	Brokerage	Analyst	Action	Rating	Price Target	Report Date Upside/Downside
7/29/2026	Royal Bank Of Canada 3 of 5 stars	Ryan Halsted Not Rated	Boost Target	Outperform	$221.00 ➝ $247.00	+0.40%
7/29/2026	TD Cowen 3 of 5 stars	Charles Rhyee Not Rated	Boost Target	Buy	$233.00 ➝ $288.00	+16.49%
7/29/2026	BMO Capital Markets 3 of 5 stars	Sean Dodge Not Rated	Boost Target	Outperform	$210.00 ➝ $270.00	+8.48%
7/29/2026	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Shlomo Rosenbaum Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$220.00 ➝ $276.00	+12.00%
7/29/2026	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Casey Woodring Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Overweight	$225.00 ➝ $285.00	+15.65%
7/29/2026	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Eric Coldwell Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Outperform	$252.00 ➝ $287.00	+16.98%
7/28/2026	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Overweight
7/28/2026	William Blair Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Strong-Buy
7/15/2026	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Hold (C-) ➝ Hold (C)
7/13/2026	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Ann Hynes Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Outperform	$215.00 ➝ $230.00	+10.51%
Get the Latest News and Ratings for IQV and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for IQVIA and its competitors with MarketBeat's FREE daily newsletter.
7/9/2026	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Set Target		$240.00	+14.43%
7/6/2026	HSBC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Buy	$240.00	+16.25%
6/17/2026	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Kallum Titchmarsh Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Overweight ➝ Equal Weight	$225.00 ➝ $200.00	+11.71%
4/8/2026	Evercore Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Elizabeth Anderson Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Outperform	$185.00	+10.93%
2/19/2026	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Jailendra Singh Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Buy	$290.00 ➝ $245.00	+48.73%
2/6/2026	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Dan Leonard Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Buy	$280.00 ➝ $240.00	+30.09%
2/6/2026	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	David Windley Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Buy	$270.00 ➝ $255.00	+36.01%
2/6/2026	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Patrick Donnelly Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Neutral	$230.00 ➝ $200.00	+6.68%
9/3/2025	Rothschild & Co Redburn Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Jamie Clark Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Set Target		$214.00	+17.92%
2/3/2025	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	David Larsen Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Downgrade	Buy ➝ Neutral
12/20/2024	Stephens Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Jeff Garro Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage	Overweight	$250.00	+30.53%
12/13/2024	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Lower Target	Buy	$255.00 ➝ $235.00	+17.54%
11/19/2024	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Outperform	$260.00 ➝ $248.00	+28.58%
11/1/2024	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Lower Target	Buy	$280.00 ➝ $250.00	+20.00%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 05:29 AM ET.

Should I Buy IQVIA Stock? IQV Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Friday, September 11, 2026. Please send any questions or comments about these IQVIA pros and cons to contact@marketbeat.com.

IQVIA
Bull Case

Here are some ways that investors could benefit from investing in IQVIA Holdings Inc.:

IQVIA Holdings Inc. recently reported strong second-quarter results, beating analyst expectations with earnings per share of $3.15 compared to the consensus estimate of $3.03, while also exceeding revenue forecasts with $4.37 billion in sales, demonstrating robust operational performance and demand for its life sciences services.
The company has established a strong upward momentum, with the stock reaching a 52-week high of $271.80 and currently trading at $262.09, which reflects a significant recovery from its 52-week low of $154.50 and indicates growing investor confidence in the firm's long-term trajectory.
IQVIA Holdings Inc. has raised its full-year 2026 earnings guidance to a range of $12.80 to $13.00 per share, which is notably higher than the consensus estimate of $12.57, signaling management's confidence in sustained growth and profitability throughout the remainder of the fiscal year.
Institutional interest in the stock has intensified, with major investors such as California State Teachers Retirement System significantly increasing its holdings by over 18,000% in the second quarter, and new positions opened by entities like BlackRock Inc. and Boston Partners, suggesting strong fundamental appeal among large-scale capital allocators.
The stock is currently trading at a price-to-earnings ratio of 22.65, which may be considered attractive for a company in the life sciences tools and services sector that is delivering double-digit revenue growth and consistently beating earnings estimates, offering a potential value entry point relative to its growth metrics.

IQVIA
Bear Case

Investors should be bearish about investing in IQVIA Holdings Inc. for these reasons:

Recent insider activity has been predominantly negative, with executives such as James G. Berkshire, Bhavik Patel, and Eric Sherbet selling a combined total of over 12,000 shares in the last few months, which can signal a lack of confidence from those with the most intimate knowledge of the company's internal operations.
IQVIA Holdings Inc. announced a $2 billion senior notes offering in September 2026 to redeem existing 2026 notes and repay revolving credit, which increases the company's debt load and may impact its financial flexibility or interest expense coverage in the near term.
The stock's beta of 1.18 indicates that IQVIA Holdings Inc. is more volatile than the broader market, meaning investors may experience larger price swings in both directions, which could be concerning for those with lower risk tolerance or shorter investment horizons.
Despite recent gains, the current stock price of $262.09 is still below the consensus price target of $241.88 reported in late August 2026, suggesting that some analysts believe the stock may be overvalued relative to its fundamental earnings power, or that the recent rally has outpaced fundamental improvements.
Short interest in the stock remains notable, with approximately 3.78 million shares shorted as of August 31, 2026, representing about 2.33% of the float, which indicates that a segment of the market is actively betting against the stock's performance and could contribute to downward pressure if sentiment shifts.

IQV Forecast - Frequently Asked Questions

According to the research reports of 17 Wall Street equities research analysts, the average twelve-month stock price forecast for IQVIA is $243.63, with a high forecast of $288.00 and a low forecast of $185.00.

17 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for IQVIA in the last year. There are currently 3 hold ratings, 13 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" IQV shares.

According to analysts, IQVIA's stock has a predicted downside of -7.05% based on their 12-month stock forecasts.

Over the previous 90 days, IQVIA's stock had 2 upgrades by analysts.

IQVIA has been rated by research analysts at Barclays, BMO Capital Markets, Deutsche Bank Aktiengesellschaft, HSBC, JPMorgan Chase & Co., Mizuho, Morgan Stanley, Robert W. Baird, Royal Bank Of Canada, Stifel Nicolaus, TD Cowen, Weiss Ratings, and William Blair in the past 90 days.

Analysts like IQVIA more than other "healthcare" companies. The consensus rating for IQVIA is Moderate Buy while the average consensus rating for "healthcare" companies is Hold. Learn more on how IQV compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With IQVIA Recommendations

MarketBeat monitors more than a dozen sources for IQVIA analyst ratings, with the most recent rating issued on 7/29/2026.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

IQVIA (IQV) Stock Forecast & Price Target